2nd scan uncovers missed prostate cancer, changes care for nearly half of patients: 4 notes
Ella Jeffries / beckershospitalreview - A second scan using prostate-specific membrane antigen positron emission tomography changed treatment plans for nearly half of patients with recurrent prostate cancer whose initial scan was negative, according to research published in the July issue of Th…
AI Summary: Follow-up prostate-specific membrane antigen (PSMA) PET imaging uncovered disease missed on initial scans and altered management in nearly half of patients. Repeat imaging revealed occult or more extensive disease, prompting switches from surveillance to definitive or systemic therapies and adjustments to radiation plans. The data argue for selective reimaging when staging is uncertain.
Breast Cancer Incidence Is Rising Rapidly Among Asian American, Native Hawaiian, and Pacific Islander Women
oncodaily - Breast cancer incidence is increasing rapidly among Asian American, Native Hawaiian, and Pacific Islander women in the United States, with especially concerning trends in early-onset disease, distant-stage diagnosis, and aggressive […]
AI Summary: New research shows a rapid rise in breast cancer incidence among Asian American, Native Hawaiian and Pacific Islander women, highlighting shifting epidemiology and unmet screening needs. The findings call for tailored public health strategies, culturally competent outreach and earlier detection efforts to address an alarming trend in populations historically considered lower risk.
A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy
medicalxpress - Researchers at The University of Texas MD Anderson Cancer Center have identified why some patients with a rare type of leukemia, called blastic plasmacytoid dendritic cell neoplasm (BPDCN), eventually develop resistance to tagraxofusp, the first Food and …
AI Summary: Researchers have identified decreased TXNRD1 and related molecular changes that appear linked to resistance against tagraxofusp in BPDCN patients. This insight exposes a plausible resistance mechanism and opens opportunities to test predictive biomarkers or combination strategies to overcome failure, which is welcome news for clinicians facing a stubborn, high‑risk disease.
First-in-human immunotherapy more than doubles progression-free survival in glioblastoma patients
medicalxpress - Glioblastoma, the most aggressive malignant brain tumor in adults, remains one of the most challenging cancers to treat because of limited treatment options and a poor prognosis. Patient outcomes have remained largely unchanged in the past two decades, un…
AI Summary: A first‑in‑human immunotherapy study in recurrent glioblastoma reported a more than twofold improvement in progression‑free survival, drawing attention to anti‑LAG‑3 strategies with or without anti‑PD‑1. While early and limited, the results provide a rare hint of efficacy in a notoriously treatment‑resistant cancer and warrant expedited follow‑up.
Young Kwang Chae: DREAM Study Highlights 100% 1-Year Survival After Lung Transplant
oncodaily - Young Kwang Chae, Professor and Co-Director of Developmental Therapeutics, Lurie Cancer Center at Northwestern University, shared a post on X: “I am happy to share our first comprehensive report of […]
AI Summary: The DREAM study reports an eye‑popping 100% one‑year survival among a very select group of lung transplant recipients, including patients with advanced lung cancer. Enthusiasm is tempered by small cohort size and selection bias concerns, but the results hint that transplantation could be a viable life‑extending option for carefully chosen patients.
American Cancer Society Reports Latest Global Cancer Statistics; Cancer Cases Approach 21 Million Worldwide, With Burden Projected to Surge 67% by 2050
cancer - New data reveal stark geographic inequities and call for urgent global action on prevention, early detection, and equitable treatment access
AI Summary: The American Cancer Society published updated global cancer statistics showing cases near 21 million and projecting a steep rise by midcentury, highlighting shifting incidence patterns and growing health system strain. The report calls for intensified prevention, screening and investment in equitable cancer control to blunt the projected surge.
- Cancer-type disparities: breast, GI, GU, hematology (5)
- Global stakeholders' reactions: calls for urgent action (4)
- GLOBOCAN/ACS 2024: Headline global cancer numbers (5)
- WHO/IARC 2026 report: launch and policy warnings (4)
- All Other Stories
Cancer-type disparities: breast, GI, GU, hematology
Global stakeholders' reactions: calls for urgent action
GLOBOCAN/ACS 2024: Headline global cancer numbers
WHO/IARC 2026 report: launch and policy warnings
All Other Stories
Parham Habibzadeh: ctDNA MRD After CRLM Resection Identifies Who Benefits From ACT!
oncodaily - Parham Habibzadeh, Internal Medicine Resident at UPMC, shared a post on X: “JAMA Oncology: ctDNA MRD after CRLM resection identifies who benefits from ACT! Upfront surgery: MRD+ patients improved with […]
AI Summary: A growing body of evidence shows circulating tumor DNA (ctDNA) measured after colorectal liver metastasis resection can identify which patients truly benefit from adjuvant chemotherapy and who likely do not. This blood test promises more personalized postoperative care, reducing unnecessary toxicity and costs by targeting chemo to molecular minimal residual disease rather than gut instinct.
Ovarian Function Suppression Plus Tamoxifen Significantly Reduces Premenopausal Breast Cancer Recurrence Over Tamoxifen and Further Reduction Is Seen When Combined with Exemestane
esmo - Findings from the SOFT and TEXT studies
AI Summary: A new analysis shows adding ovarian function suppression to tamoxifen substantially lowers recurrence in premenopausal breast cancer patients compared with tamoxifen alone, with even greater reduction when switched to exemestane. Clinicians should note the clear endocrine benefit — and patients can sigh with cautious optimism while weighing menopausal side effects.
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Wanxiang Shen / nature - Nature Medicine, Published online: 03 July 2026; doi:10.1038/s41591-026-04502-7COMPASS is a pan-cancer foundation model that predicts immunotherapy response, across cancer types and treatments, from bulk tumor transcriptomes.
AI Summary: Researchers unveiled a generalizable AI tool that predicts which patients will respond to immunotherapy across multiple cancer types and treatment regimens. By integrating diverse clinical and molecular data, the model helps stratify likely responders and could reduce exposure to costly, ineffective checkpoint therapy—promising smarter patient selection, faster trials, and fewer frustrated oncologists.
- COMPASS: pan-cancer AI predicting immunotherapy response (6)
- Tumor-specific predictors and clinical nuance in immunotherapy (3)
COMPASS: pan-cancer AI predicting immunotherapy response
Tumor-specific predictors and clinical nuance in immunotherapy
CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camelia Benlabiod, / science - Science Translational Medicine, Volume 18, Issue 856, July 2026.
AI Summary: Preclinical studies show CAR‑T cells engineered to target mutant calreticulin selectively eliminate disease‑driving clones in xenografts and human organoid models of myelofibrosis. The results reveal a potentially curative approach for a previously intractable mutation‑driven disease, though safety, on‑target effects and clinical translation remain to be rigorously tested.
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Stephanie Gomez / nature - Nature Medicine, Published online: 30 June 2026; doi:10.1038/s41591-026-04449-9In the phase 1 ReMIND trial of tumor-associated antigen-specific T cells in patients with pediatric central nervous system tumors, treatment was generally well tolerated with o…
AI Summary: A phase I trial of multi‑antigen‑targeted T cells for aggressive pediatric CNS tumors reported early survival and safety signals, suggesting these engineered cells can engage heterogeneous tumor antigens. Investigators emphasize cautious optimism: encouraging early responses in a dire setting, but longer follow‑up and larger cohorts are needed before this becomes standard‑of‑care.
CheckMate 214 Updates: Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced RCC
oncodaily - First-line treatment for advanced renal cell carcinoma has changed substantially with the use of immune checkpoint inhibitor-based regimens. Long-term follow-up is important to show whether these early survival and response […]
AI Summary: Long‑term CheckMate‑214 data comparing nivolumab plus ipilimumab against sunitinib in advanced renal cell carcinoma show sustained survival benefits for the immunotherapy combination at nine years. The follow‑up reinforces durable responses in a defined subgroup, helping clinicians refine long‑term treatment sequencing and expectations for metastatic RCC.
EMERALD-3 at ESMO GI 2026: Tremelimumab Plus Durvalumab With or Without Lenvatinib Plus TACE in Embolisation-Eligible HCC
oncodaily - In the Proffered Paper session, Joseph P. Erinjeri from New York, United States, presented updated tumour response analyses from the phase III EMERALD-3 study. The abstract, titled “Tumour response analyses […]
AI Summary: EMERALD‑3, presented at ESMO GI 2026, evaluates tremelimumab plus durvalumab with or without lenvatinib and TACE in embolisation‑eligible hepatocellular carcinoma. The trial probes whether adding systemic immunotherapy to locoregional strategies improves outcomes for patients traditionally steered toward embolisation, potentially redefining combination approaches in intermediate‑stage HCC.
Bacteria-killing viruses redirect vaccine immunity to destroy cancer
newscientist - Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from vaccines
AI Summary: Researchers show bacteriophages can redirect existing vaccine‑induced immunity to attack cancer cells, effectively hijacking antiviral immune memory to target tumours. This clever preclinical strategy repurposes phages as delivery vehicles and immunomodulators, opening a potential new class of off‑the‑shelf immunotherapies that could complement or bypass current T‑cell approaches — if it survives the usual valley of translation.
Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories
Agenus releases Phase 1b three-year BOT+BAL survival data
Clinical and community reaction: experts weigh in on BOT+BAL
ESMO GI: BOT+BAL benefits in patients without active liver metastases
All Other Stories
RWJBarnabas Health, Rutgers open $225M cancer center
Elizabeth Gregerson / beckershospitalreview - On June 22, West Orange, N.J.-based RWJBarnabas Health and New Brunswick, N.J.-based Rutgers Cancer Institute opened the Melchiorre Cancer Center at Cooperman Barnabas Medical Center in Livingston, N.J. The cancer center cost $225 million, according to a …
AI Summary: Results presented at ASCO for daraxonrasib delivered practice‑changing evidence in pancreatic cancer, prompting clinicians to offer the drug off‑trial within weeks. The data generated excitement across conferences and clinical teams, fueling early adoption discussions and raising hopes for a tangible advance against a historically stubborn disease.
- ASCO shockwave: Daraxonrasib survival curve draws standing ovation (3)
- Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing (4)
- Conference context: RAS momentum and expert reflections (5)
- Rapid off‑trial rollout and early patient access (4)
- All Other Stories
ASCO shockwave: Daraxonrasib survival curve draws standing ovation
Competing KRAS strategies: zoldonrasib, HRS‑4642 and blood testing
Conference context: RAS momentum and expert reflections
Rapid off‑trial rollout and early patient access
All Other Stories
FDA Approves Gilead’s Trodelvy, Alone and With Merck’s Keytruda, in First-Line Metastatic TNBC
oncodaily - Decision delivers the first ADC-based regimens for previously untreated triple-negative breast cancer across PD-L1 status, a PD-L1-positive Keytruda combination plus a monotherapy option for immunotherapy-ineligible patients. The U.S. Food and […]
AI Summary: The FDA approved sacituzumab govitecan (Trodelvy) as both monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of metastatic triple‑negative breast cancer, expanding options for a hard-to-treat population. Regulators cited clinical benefit in appropriate patients, reshaping treatment sequencing and payer discussions.
FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Medical Journal Retracts Study Claiming Cancer Therapy Is More Effective When Given in the Morning
Rebecca Robbins / nytimes - In a notice flagging a series of problems with a clinical trial, the journal Nature Medicine said its editors “no longer have confidence in the integrity of the results.”
AI Summary: A high‑profile medical journal retracted a paper that claimed cancer immunotherapy is significantly more effective when administered in the morning. The reversal follows scrutiny over methods and data integrity, prompting clinicians to pause any scheduling changes until robust evidence actually materializes.